NCT02086656View on ClinicalTrials.gov

PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

March 30, 2017

Study Completion Date

March 30, 2017

Conditions
Colorectal Cancer Liver Metastases
Interventions
DRUG

capecitabine, oxaliplatin, irinotecan and bevacizumab

perioperative COI-B

Trial Locations (1)

20133

Fondazione IRCCS Istituto Nazionale Tumori, Milan

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT02086656 - PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES | Biotech Hunter | Biotech Hunter